Loading…
Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study
Purpose To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs. Methods Dogs with signs and symptoms of KCS were block‐randomiz...
Saved in:
| Published in: | Veterinary ophthalmology 2024-09, Vol.27 (5), p.461-468 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2850-5e38ed9bcd0238a870019090e09833607f43b75c7594db84a96b7c27e4d5b4e03 |
| container_end_page | 468 |
| container_issue | 5 |
| container_start_page | 461 |
| container_title | Veterinary ophthalmology |
| container_volume | 27 |
| creator | García‐Santisteban, Rodrigo Linares‐Alba, Mónica Anayatzin Botello‐Bárcenas, Andrés Margay, Paola Soto, Carlos Fonzar‐Furtado, Joice Brooks, Dennis García, Diego Sánchez, Gustavo Adolfo García |
| description | Purpose
To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs.
Methods
Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests (p |
| doi_str_mv | 10.1111/vop.13190 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2923911268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2923911268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2850-5e38ed9bcd0238a870019090e09833607f43b75c7594db84a96b7c27e4d5b4e03</originalsourceid><addsrcrecordid>eNp1kclOHDEQhq0IFJbkkBdAPgaJGex2b84NobBISETKcm15qUEm7nbH5Z5oOPEIXHm9PEkMw3LClyqpPn2S_5-QT5zNeX6HyzDOueCSvSPbvKzFrCqKcuNl5_UW2UG8ZoyJijXvyZZoRSELKbfJ_fdJmzBcT4NJbqk89W4MGPq8oYvBu35CusQ5NSvjA44hugFoiDQp83xWSFMElXoYEg0L-huiSuHV6pLDbDNGUTdQG67wCz3Kc9Ie_t3eae8Ge0CjGmzo3Q1Yimmyqw9kc6E8wsenuUt-nnz9cXw2u7g8PT8-upiZoq3YrALRgpXaWFaIVrUNYzkIyYDJVoiaNYtS6KYyTSVLq9tSyVo3pmigtJUugYld8nntHWP4MwGmrndowHs1QJiwy0EJyXlRtxndX6P564gRFt0YXa_iquOse2iiy010j01kdu9JO-ke7Av5HH0GDtfAX-dh9bap-3X5ba38D7iKlzk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2923911268</pqid></control><display><type>article</type><title>Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study</title><source>Wiley</source><creator>García‐Santisteban, Rodrigo ; Linares‐Alba, Mónica Anayatzin ; Botello‐Bárcenas, Andrés ; Margay, Paola ; Soto, Carlos ; Fonzar‐Furtado, Joice ; Brooks, Dennis ; García, Diego ; Sánchez, Gustavo Adolfo García</creator><creatorcontrib>García‐Santisteban, Rodrigo ; Linares‐Alba, Mónica Anayatzin ; Botello‐Bárcenas, Andrés ; Margay, Paola ; Soto, Carlos ; Fonzar‐Furtado, Joice ; Brooks, Dennis ; García, Diego ; Sánchez, Gustavo Adolfo García</creatorcontrib><description>Purpose
To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs.
Methods
Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests (p < .05 was considered significant).
Results
A total of 30 eyes were included in the study, of which 20 eyes completed follow‐up. There was no statistically significant interaction between the treatment group and time on STT‐1 score (p = .165), and median CH and CO scores showed no statistically significant differences between groups (p = .353 and p = .393, respectively). There were no clinically significant side effects present in any subject at any time.
Conclusion
In this trial, a 1 mg/mL (100 micrograms) SCJS every 2 weeks showed similar safety and efficacy profiles as daily CsA/T in dogs with KS after 14 weeks of treatment. Larger studies should be performed to further assess SCJS as an alternative treatment for KCS.</description><identifier>ISSN: 1463-5216</identifier><identifier>ISSN: 1463-5224</identifier><identifier>EISSN: 1463-5224</identifier><identifier>DOI: 10.1111/vop.13190</identifier><identifier>PMID: 38329299</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Cyclosporine - administration & dosage ; Cyclosporine - therapeutic use ; Dog Diseases - drug therapy ; Dogs ; Double-Blind Method ; dry eye ; Female ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Keratoconjunctivitis Sicca - drug therapy ; Keratoconjunctivitis Sicca - veterinary ; Liposomes ; Male ; nanotechnology ; Sirolimus ; Sirolimus - administration & dosage ; Sirolimus - therapeutic use ; Tacrolimus - administration & dosage ; Tacrolimus - therapeutic use ; Treatment Outcome</subject><ispartof>Veterinary ophthalmology, 2024-09, Vol.27 (5), p.461-468</ispartof><rights>2024 American College of Veterinary Ophthalmologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2850-5e38ed9bcd0238a870019090e09833607f43b75c7594db84a96b7c27e4d5b4e03</cites><orcidid>0000-0002-7939-5222</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38329299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García‐Santisteban, Rodrigo</creatorcontrib><creatorcontrib>Linares‐Alba, Mónica Anayatzin</creatorcontrib><creatorcontrib>Botello‐Bárcenas, Andrés</creatorcontrib><creatorcontrib>Margay, Paola</creatorcontrib><creatorcontrib>Soto, Carlos</creatorcontrib><creatorcontrib>Fonzar‐Furtado, Joice</creatorcontrib><creatorcontrib>Brooks, Dennis</creatorcontrib><creatorcontrib>García, Diego</creatorcontrib><creatorcontrib>Sánchez, Gustavo Adolfo García</creatorcontrib><title>Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study</title><title>Veterinary ophthalmology</title><addtitle>Vet Ophthalmol</addtitle><description>Purpose
To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs.
Methods
Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests (p < .05 was considered significant).
Results
A total of 30 eyes were included in the study, of which 20 eyes completed follow‐up. There was no statistically significant interaction between the treatment group and time on STT‐1 score (p = .165), and median CH and CO scores showed no statistically significant differences between groups (p = .353 and p = .393, respectively). There were no clinically significant side effects present in any subject at any time.
Conclusion
In this trial, a 1 mg/mL (100 micrograms) SCJS every 2 weeks showed similar safety and efficacy profiles as daily CsA/T in dogs with KS after 14 weeks of treatment. Larger studies should be performed to further assess SCJS as an alternative treatment for KCS.</description><subject>Animals</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Double-Blind Method</subject><subject>dry eye</subject><subject>Female</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Keratoconjunctivitis Sicca - drug therapy</subject><subject>Keratoconjunctivitis Sicca - veterinary</subject><subject>Liposomes</subject><subject>Male</subject><subject>nanotechnology</subject><subject>Sirolimus</subject><subject>Sirolimus - administration & dosage</subject><subject>Sirolimus - therapeutic use</subject><subject>Tacrolimus - administration & dosage</subject><subject>Tacrolimus - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1463-5216</issn><issn>1463-5224</issn><issn>1463-5224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kclOHDEQhq0IFJbkkBdAPgaJGex2b84NobBISETKcm15qUEm7nbH5Z5oOPEIXHm9PEkMw3LClyqpPn2S_5-QT5zNeX6HyzDOueCSvSPbvKzFrCqKcuNl5_UW2UG8ZoyJijXvyZZoRSELKbfJ_fdJmzBcT4NJbqk89W4MGPq8oYvBu35CusQ5NSvjA44hugFoiDQp83xWSFMElXoYEg0L-huiSuHV6pLDbDNGUTdQG67wCz3Kc9Ie_t3eae8Ge0CjGmzo3Q1Yimmyqw9kc6E8wsenuUt-nnz9cXw2u7g8PT8-upiZoq3YrALRgpXaWFaIVrUNYzkIyYDJVoiaNYtS6KYyTSVLq9tSyVo3pmigtJUugYld8nntHWP4MwGmrndowHs1QJiwy0EJyXlRtxndX6P564gRFt0YXa_iquOse2iiy010j01kdu9JO-ke7Av5HH0GDtfAX-dh9bap-3X5ba38D7iKlzk</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>García‐Santisteban, Rodrigo</creator><creator>Linares‐Alba, Mónica Anayatzin</creator><creator>Botello‐Bárcenas, Andrés</creator><creator>Margay, Paola</creator><creator>Soto, Carlos</creator><creator>Fonzar‐Furtado, Joice</creator><creator>Brooks, Dennis</creator><creator>García, Diego</creator><creator>Sánchez, Gustavo Adolfo García</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7939-5222</orcidid></search><sort><creationdate>202409</creationdate><title>Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study</title><author>García‐Santisteban, Rodrigo ; Linares‐Alba, Mónica Anayatzin ; Botello‐Bárcenas, Andrés ; Margay, Paola ; Soto, Carlos ; Fonzar‐Furtado, Joice ; Brooks, Dennis ; García, Diego ; Sánchez, Gustavo Adolfo García</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2850-5e38ed9bcd0238a870019090e09833607f43b75c7594db84a96b7c27e4d5b4e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Double-Blind Method</topic><topic>dry eye</topic><topic>Female</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Keratoconjunctivitis Sicca - drug therapy</topic><topic>Keratoconjunctivitis Sicca - veterinary</topic><topic>Liposomes</topic><topic>Male</topic><topic>nanotechnology</topic><topic>Sirolimus</topic><topic>Sirolimus - administration & dosage</topic><topic>Sirolimus - therapeutic use</topic><topic>Tacrolimus - administration & dosage</topic><topic>Tacrolimus - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García‐Santisteban, Rodrigo</creatorcontrib><creatorcontrib>Linares‐Alba, Mónica Anayatzin</creatorcontrib><creatorcontrib>Botello‐Bárcenas, Andrés</creatorcontrib><creatorcontrib>Margay, Paola</creatorcontrib><creatorcontrib>Soto, Carlos</creatorcontrib><creatorcontrib>Fonzar‐Furtado, Joice</creatorcontrib><creatorcontrib>Brooks, Dennis</creatorcontrib><creatorcontrib>García, Diego</creatorcontrib><creatorcontrib>Sánchez, Gustavo Adolfo García</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García‐Santisteban, Rodrigo</au><au>Linares‐Alba, Mónica Anayatzin</au><au>Botello‐Bárcenas, Andrés</au><au>Margay, Paola</au><au>Soto, Carlos</au><au>Fonzar‐Furtado, Joice</au><au>Brooks, Dennis</au><au>García, Diego</au><au>Sánchez, Gustavo Adolfo García</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study</atitle><jtitle>Veterinary ophthalmology</jtitle><addtitle>Vet Ophthalmol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>27</volume><issue>5</issue><spage>461</spage><epage>468</epage><pages>461-468</pages><issn>1463-5216</issn><issn>1463-5224</issn><eissn>1463-5224</eissn><abstract>Purpose
To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs.
Methods
Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests (p < .05 was considered significant).
Results
A total of 30 eyes were included in the study, of which 20 eyes completed follow‐up. There was no statistically significant interaction between the treatment group and time on STT‐1 score (p = .165), and median CH and CO scores showed no statistically significant differences between groups (p = .353 and p = .393, respectively). There were no clinically significant side effects present in any subject at any time.
Conclusion
In this trial, a 1 mg/mL (100 micrograms) SCJS every 2 weeks showed similar safety and efficacy profiles as daily CsA/T in dogs with KS after 14 weeks of treatment. Larger studies should be performed to further assess SCJS as an alternative treatment for KCS.</abstract><cop>England</cop><pmid>38329299</pmid><doi>10.1111/vop.13190</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7939-5222</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1463-5216 |
| ispartof | Veterinary ophthalmology, 2024-09, Vol.27 (5), p.461-468 |
| issn | 1463-5216 1463-5224 1463-5224 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2923911268 |
| source | Wiley |
| subjects | Animals Cyclosporine - administration & dosage Cyclosporine - therapeutic use Dog Diseases - drug therapy Dogs Double-Blind Method dry eye Female Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Keratoconjunctivitis Sicca - drug therapy Keratoconjunctivitis Sicca - veterinary Liposomes Male nanotechnology Sirolimus Sirolimus - administration & dosage Sirolimus - therapeutic use Tacrolimus - administration & dosage Tacrolimus - therapeutic use Treatment Outcome |
| title | Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A14%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subconjunctival%20liposomal%20sirolimus%20vs.%20cyclosporine%20or%20tacrolimus%20as%20treatment%20of%20keratoconjunctivitis%20sicca%20in%20dogs:%20A%20double%E2%80%90blind,%20randomized%20study&rft.jtitle=Veterinary%20ophthalmology&rft.au=Garc%C3%ADa%E2%80%90Santisteban,%20Rodrigo&rft.date=2024-09&rft.volume=27&rft.issue=5&rft.spage=461&rft.epage=468&rft.pages=461-468&rft.issn=1463-5216&rft.eissn=1463-5224&rft_id=info:doi/10.1111/vop.13190&rft_dat=%3Cproquest_cross%3E2923911268%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2850-5e38ed9bcd0238a870019090e09833607f43b75c7594db84a96b7c27e4d5b4e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2923911268&rft_id=info:pmid/38329299&rfr_iscdi=true |